Viral Hepatitis Research Foundation

Email

mkasuya@sunny.ocn.ne.jp

Phone

T: 113-0033 3-2-15

Web

www.vhfj.or.jp

Address

3-2-15 Hongo, Bunkyo-ku, Tokyo 113-0033 Japan
About Viral Hepatitis Research Foundation

Main objectives and activities:

The Viral Hepatitis Research Foundation promotes research works, improves diagnosis and treatments and prevents viral hepatitis, and also promotes public awareness by campaign.

1. Research activities to develope diagnosis, prevention and treatment of viral hepatitis.

  • A few research residents who work in the research laboratories have been adopted for few years, in order to promote global or interdisciplinary research in the field of viral hepatitis.

2. Activities for campaigns on viral hepatitis to enlighten public awareness. 

  • The open lectures on viral hepatitis are held for citizen to enlighten public awareness.
  • Advertisements on viral hepatitis in the streets are done to give better awareness.

3.Activities for cooperation to national and international communications on viral hepatitis.

  • Excellent researchers in the field of viral hepatitis have been invited from foreign countries.
  • Japanese researchers have been sent to developed or developing countries to get an interchange of research data between countries.

4. Assists for Hepatitis-Control Measures by Ministry of Health, Labour and Welfare.

  • An open meeting is held once a year for chief researchers to summarize the latest results. 

5. Activities to consult and advise on viral hepatitis.

  • A course for education to the persons in charge of areas on viral hepatitis guide is held every year for two days.
  • Answering the questions from citizens on viral hepatitis by emails, telephones and letters.  

Sign up to receive updates from WHA

Name(Required)
I would like to hear about(Required)

We use Mailchimp as our marketing platform. By clicking below to subscribe, you acknowledge that your information will be transferred to Mailchimp for processing. Learn more about Mailchimp's privacy practices.

Hepatitis and PWID/harm reduction 

 

11:35 – 11:40  

Chair: WHO – Intro and set the scene.  

 

11:40 – 11:55  

Co-chair:  EMCDDA – Monitoring viral hepatitis elimination among PWID in Europe. 

 

11:55 – 12:00 

ID 29: Ema Pos (not yet registered) 

Title: If the mountain won’t come to Mohammed: lessons from a decentralized Infectious Disease consultation. 

 

12:05 – 12:10  

ID 152: Brian Conway (Registered in person) 

Title: Community Pop-up Clinic: Cascade of Care and HCV Treatment of Vancouver’s inner-city PWID Populations.

 

12:10 – 12:15 

ID 212: Jasmine West (not yet registered) 

Title: From lived experience to lived expertise: a syndemic approach. 

 

12:15 – 12:20 

ID: 299 Mercy Nyakowa (Registered in person) 

Title: HCV and HBV prevalence and associated risk factors among people who inject drugs (PWIDs) in Kenya 

 

12:20 – 12:25 

ID: 133 Nalinikanta Rajkumar (Registered in person) 

Title: Rapid regimen of HBV vaccination: Does it work for high risk groups?  

 

12:25 – 12:30 

Q&A and closing remarks   

tHIS

 

IS 

 

BEN’S

 

 

 

BIG 

 

 

TEST

effective case finding strategies

Supported by Vir Biotechnology, Inc

During this session you will hear from hepatitis Delta expert, Dr. Maria Buti, and a patient who has lived with hepatitis Delta in a panel discussion moderated by Dr. Carey Hwang, Chief Medical Officer (interim) of Vir Biotechnology. This panel will inform perspectives on patient needs, opportunities for enhanced screening, and strengthening linkages to care.

Session Agenda

14:40 – 14:45    

Panel overview and introductions facilitated by Dr Carey Hwang (Vir Biotechnology)

14:45 – 15:05   

Panel discussion: Dr Maria Buti (University Hospital Vall d’Hebron, Spain), Milanka Barbosa, Dr Carey Hwang (Chief Medical Officer interim), Vir Biotechnology

15:05 – 15:10    

Final remarks and close